-
EP1313461
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1313461
| EP1313461 - THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 15.07.2005 Database last updated on 02.11.2024 | Most recent event Tooltip | 15.07.2005 | Application deemed to be withdrawn | published on 31.08.2005 [2005/35] | Applicant(s) | For all designated states Melacure Therapeutics AB Uller kersvägen 38 756 43 Uppsala / SE | [2003/22] | Inventor(s) | 01 /
LUNDSTEDT, Torbjörn Granelidsvägen 7B S-756 55 Uppsala / SE | 02 /
SKOTTNER, Anna Lobov. 3 S-178 32 Ekerö / SE | 03 /
SEIFERT, Elisabeth Rotyxv. 17 S-756 48 Uppsala / SE | [2003/22] | Representative(s) | Pett, Christopher Phineas Dehns St Bride's House 10 Salisbury Square London EC4Y 8JD / GB | [N/P] |
| Former [2003/22] | Pett, Christopher Phineas Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street London EC4V 4EL / GB | Application number, filing date | 01954176.2 | 07.08.2001 | [2003/22] | WO2001GB03534 | Priority number, date | GB20000019357 | 07.08.2000 Original published format: GB 0019357 | [2003/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0211715 | Date: | 14.02.2002 | Language: | EN | [2002/07] | Type: | A2 Application without search report | No.: | EP1313461 | Date: | 28.05.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.02.2002 takes the place of the publication of the European patent application. | [2003/22] | Search report(s) | International search report - published on: | EP | 16.01.2003 | Classification | IPC: | A61K31/155 | [2003/22] | CPC: |
A61K31/155 (EP,KR,US);
C07C281/16 (US);
A61K31/185 (KR);
A61K31/205 (KR);
A61P1/04 (EP);
A61P1/14 (EP);
A61P1/16 (EP);
A61P1/18 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/06 (EP);
A61P13/12 (EP);
A61P15/00 (EP);
A61P15/04 (EP);
A61P15/06 (EP);
A61P15/08 (EP);
A61P15/10 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/04 (EP);
A61P17/06 (EP);
A61P17/08 (EP);
A61P17/16 (EP);
A61P19/02 (EP);
A61P19/04 (EP);
A61P21/00 (EP);
A61P25/00 (EP);
A61P25/02 (EP);
A61P25/04 (EP);
A61P25/18 (EP);
A61P25/22 (EP);
A61P25/24 (EP);
A61P25/28 (EP);
A61P25/32 (EP);
A61P25/36 (EP);
A61P27/02 (EP);
A61P29/00 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P31/04 (EP);
A61P31/12 (EP);
A61P31/18 (EP);
A61P33/02 (EP);
A61P33/10 (EP);
A61P35/00 (EP);
A61P35/04 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/04 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P39/00 (EP);
A61P39/02 (EP);
A61P43/00 (EP);
A61P5/00 (EP);
A61P5/06 (EP);
A61P5/10 (EP);
A61P5/14 (EP);
A61P5/30 (EP);
A61P5/40 (EP);
A61P7/00 (EP);
A61P7/02 (EP);
A61P7/04 (EP);
A61P7/06 (EP);
A61P7/08 (EP);
A61P7/10 (EP);
A61P9/00 (EP);
A61P9/02 (EP);
A61P9/04 (EP);
A61P9/06 (EP);
A61P9/08 (EP);
A61P9/10 (EP);
A61P9/12 (EP);
A61P9/14 (EP);
C07C309/30 (US);
C07C309/46 (US);
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/22] | Extension states | AL | 07.03.2003 | LT | 07.03.2003 | LV | 07.03.2003 | MK | 07.03.2003 | RO | 07.03.2003 | SI | 07.03.2003 | Title | German: | DIE VERWENDUNG VON BENZYLIDENAMINOGUANIDINEN UND HYDROXYGUANIDINEN ALS LIGANDEN DES MELANOCORTINREZEPTORS | [2003/22] | English: | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | [2003/22] | French: | BENZYLIDENEAMINOGUANIDINES ET HYDROXYGUANIDINES UTILISEES COMME LIGANDS DES RECEPTEUR DE LA MELANOCORTINE | [2003/22] | Entry into regional phase | 07.03.2003 | National basic fee paid | 07.03.2003 | Designation fee(s) paid | 07.03.2003 | Examination fee paid | Examination procedure | 06.03.2002 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 07.03.2003 | Amendment by applicant (claims and/or description) | 07.03.2003 | Examination requested [2003/22] | 01.03.2005 | Application deemed to be withdrawn, date of legal effect [2005/35] | 04.04.2005 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2005/35] | Fees paid | Renewal fee | 25.08.2003 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.08.2004 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]DE2020230 (ANVAR, et al) [A] 9 * example 2 *; | [X]US3592935 (HOULIHAN WILLIAM J, et al) [X] 1-13 * See compounds in example 1 *;; claim 1 * * column 1, lines 21,42-44 *; | [X]US3896232 (HOULIHAN WILLIAM J, et al) [X] 1-13 * claim 1 *; | [X]US3982020 (HOULIHAN WILLIAM J, et al) [X] 1-13,27 * See compounds in example 2 *; column 1, line 15; claim 1 *; | [X]US4006250 (CHILDRESS SCOTT J) [X] 1-13 * example -; claim - *; | [A]DE3428342 (BOEHRINGER INGELHEIM VETMED [DE]) [A] 1,2,7,8,24 * See table 1, compound 4;; claim - *; | [A]WO9303714 (UPJOHN CO [US]) [A] * See compounds N.78, 85,115;; claims 1,4 *; | [Y]US5599984 (BIANCHI MARINA [IT], et al) [Y] 1-13 * the whole document *; | [A]US5750573 (BIANCHI MARINA [IT], et al) [A] 1,2,7,8,24 * column 2, line 45 - column 3, line 11 * * column 18, lines 47,48 * * Figure 7a, compound 7; column 7, lines 12-14 *; | [XDY]WO9823267 (WAPHARM AB [SE], et al) [XD] 1-13 * page 5, line 43 * * See compounds of Table 1 *;; example - * * page 12, line 19 * [Y] 1-13; | [PX]WO0125192 (MELACURE THERAPEUTICS AB [SE], et al) [PX] 1-13,51 * See claim 16 compounds :1:2; 1:7; 1:45; 1:121; 1:122 *;; examples 11,12; claims 39,51 * * page 8, line 11 - page 12, line 14 *; | [X] - CHANG J ET AL, "THE ANTIINFLAMMATORY ACTION OF GUANABENZ IS MEDIATED THROUGH 5-LIPOXYGENASE AND CYCLOOXYGENASE INHIBITION", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, (1987), vol. 142, no. 2, ISSN 0014-2999, pages 197 - 205, XP000974753 [X] 1-13 * the whole document * DOI: http://dx.doi.org/10.1016/0014-2999(87)90108-7 | [A] - DIMMOCK J R ET AL, "EVALUATION OF THE THIOSEMICARBAZONES OF SOME ARYL ALKYL KETONES AND RELATED COMPOUNDS FOR ANTICONVULSANT ACTIVITIES", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, (1991), vol. 26, no. 5, ISSN 0223-5234, pages 529 - 534, XP002014742 [A] 1-13 * the whole document * DOI: http://dx.doi.org/10.1016/0223-5234(91)90148-G | [A] - FOYE W O ET AL, "Synthesis and Biological Activity of Guanylhydrazones of 2- and 4-Pyridine and 4-Quinoline Carboxaldehydes", JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION. SCIENTIFIC EDITION, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, (199006), vol. 79, no. 6, pages 527 - 530, XP002180467 [A] 1-13 * the whole document * | [A] - SOUTHAN GARRY J ET AL, "Hydroxyguanidines inhibit peroxynitrite-induced oxidation.", FREE RADICAL BIOLOGY & MEDICINE, (19981115), vol. 25, no. 8, ISSN 0891-5849, pages 914 - 925, XP002209697 [A] 9 * table 1 * DOI: http://dx.doi.org/10.1016/S0891-5849(98)00120-8 | [X] - KAZIC, T. ET AL, "Central presynaptic alpha2 agonists guanabenz and clonidine act as alpha1 adrenoceptor antagonists in the isolated vas deferens of the guinea pig", IUGOSL. PHYSIOL. PHARMACOL. ACTA (1994), 30(1), 25-34, XP001098531 [X] 1,2,7,8,16 * the whole document * | [X] - OSAWA Y ET AL, "Inactivation of penile nitric oxide synthase by Guanabenz, an antihypertensive agent: Potential implications in drug induced impotence.", FASEB JOURNAL, Annual Meeting of the American Society for Biochemistry and Molecular Biology;San Francisco, California, USA; May 21-25, 1995, (1995), vol. 9, no. 6, ISSN 0892-6638, page A1495, XP001095624 [X] 1,2,7,8,24 * abstract * | [X] - NAKATSUKA MIKIYA ET AL, "Metabolism-based inactivation of penile nitric oxide synthase activity by Guanabenz.", DRUG METABOLISM AND DISPOSITION, (199805), vol. 26, no. 5, ISSN 0090-9556, pages 497 - 501, XP001095628 [X] 1,2,7,8,16 * the whole document * | [X] - BENELLI A ET AL, "Male sexual behaviour: further studies on the role of alpha 2-adrenoceptors.", PHARMACOLOGICAL RESEARCH: THE OFFICIAL JOURNAL OF THE ITALIAN PHARMACOLOGICAL SOCIETY. ENGLAND 1993 JUL-AUG, (199307), vol. 28, no. 1, ISSN 1043-6618, pages 35 - 45, XP001095156 [X] 1,2,7,8,24 * the whole document * DOI: http://dx.doi.org/10.1006/phrs.1993.1107 |